Allergan, an AbbVie company, today announced that the Phase 3 VIRGO trial evaluating the safety and efficacy of investigational twice-daily administration of VUITY™ (pilocarpine HCl ophthalmic solution) 1.25% in adults with presbyopia met its primary efficacy endpoint, improving near vision without compromising distance vision at Hour 9 (3 hours after the second drop) on Day…
eTurboNews amanqaku ngababhalisi kuphela. Umrhumo ngu fREE.
Ababhalisi bangena apha Cofa apha ukuze ubhalise FREE
Ababhalisi bangena apha Cofa apha ukuze ubhalise FREE
INTO ONOKUYITHATHA KWELI NQAKU:
- 25% in adults with presbyopia met its primary efficacy endpoint, improving near vision without compromising distance vision at Hour 9 (3 hours after the second drop) on Day….
- Umrhumo SIMAHLA.
- Allergan, an AbbVie company, today announced that the Phase 3 VIRGO trial evaluating the safety and efficacy of investigational twice-daily administration of VUITY™ (pilocarpine HCl ophthalmic solution) 1.
